Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: Mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 12, 2003, Pages 1535-1543

  Scheiman, J M ^a,b,d   Greenson, J K ^a,b   Lee, J ^b   Cryer, B ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN; PROSTAGLANDIN E2; ROFECOXIB;

ADULT; ARTICLE; BIOSAFETY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOSCOPIC BIOPSY; FEMALE; GASTRITIS; GASTROINTESTINAL TRACT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK; SCORING SYSTEM; STOMACH ANTRUM; STOMACH MUCOSA; STOMACH ULCER;

ADULT; CELL DIVISION; CYCLOOXYGENASE 2; DINOPROSTONE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYLORIC ANTRUM; STOMACH; STOMACH NEOPLASMS; SULFONES;

EID: 0038574389     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01587.x     Document Type: Article

References (30)

1. Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med 1999; 106: 222-6.
2. Ruiz B, Garay J, Correa P, et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. Am J Gastroenterol 2001; 96: 3281-7.
3. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 7-14.
4. Krishnan K, Brenner DE. Prostaglandin inhibitors and the chemoprevention of noncolonic malignancy. Gastroenterol Clinics North Am 2001; 30: 981-1000.
5. Sung JJ, Leung WK, Go MY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000; 157: 729-35.
6. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-80.
7. Zhu GH, Yang XL, Lai KC, et al. Nonsteroidal antiinflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells. Dig Dis Sci 1998; 43: 1957-63.
8. Hudson N, Balsitis M, Filipowicz F, et al. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 748-51.
9. Hawkey C, Laine L, Simon TE, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arth Rheum 2000; 43: 370-7.
10. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1505-84.
11. Wright NJ, Gottesdiener K, Garlick NM, et al. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 2001; 120: 867-73.
12. Hawkey CJ, Laine L, Harper SE, et al. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001; 15: 1593-601.
13. Chan FK, To KF, Ng YP, et al. Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis. Aliment Pharmacol Ther 2001; 15: 187-93.
14. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandins levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 7-25.
15. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis: The updated Sydney System. Am J Surg Pathol 1996; 20: 1161-81.
16. McCarthy CJ, Crofford LJ, Greenson J, et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 1218-23.
17. Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999; 116: 1319-29.
18. Feldman M, Cryer B, Mallat D, Go MF. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial. Am J Gastroenterol 2001; 96: 1751-7.
19. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric cancer or duodenal ulcer disease. N Engl J Med 1996; 335: 242-9.
20. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet: 2002; 359(9300): 14-22.
21. Jackson LM, Wu KC, Mahida YR, et al. Cyclooxygenase (COX) 1 and 2 in normal inflamed and ulcerated human gastric mucosa. Gut 2000; 47: 762-70.
22. Laine L, Bombardier C, Hawkey C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenteol 2002; 123: 1006-12.
23. Gupta RA, Dubois RN. Colorectal, cancer prevention and treatment by inhibition of cyloxygenase-2. Natl Rev Cancer 2001; 1: 11-21.
24. Hussain SS, Szabo IL, Tarnawski AS. NSAID Inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastoenterol 2002; 97: 542-53.
25. 2 synthesis in MKN 28 gastric mucosal cells in vitro. J Bio Chem 1998; 273: 28 560-3.
26. Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of H. pylori screening to prevent gastric cancer. Arch Int Med 1999; 159: 142-8.
27. Fraser AG, Sim R, Sankey EA, et al. Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation. Aliment Pharm Ther 1994; 8: 167-73.
28. Levi S, Goodlad RA, Lee CY, et al. Effects of nonsteroidal anti-inflammatory drugs and misoprostol on gastroduodenal epithelial proliferation in arthritis. Gastroenterology 1992; 102: 1605-11.
29. Tseng GY, Lin HJ, Lin HY, et al. Effect of non-steroidal anti-inflammatory drugs on gastric and duodenal prostaglandin concentrations in patients with Helicobacter pylori infection. Hepatogastroenterology 1999; 46: 1000-4.
30. Kaur BS, Khamnehei N, Iravani M, et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-7.